INTEC PHARMA LTD. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2018-07: Study NCT03576638; Company role Lead sponsor; Phase Phase 2; Status Unknown.
- 2016-07: Study NCT02615873; Company role Lead sponsor; Phase Phase 3; Status Unknown.
- 2016-03: Study NCT02605434; Company role Lead sponsor; Phase Phase 3; Status Unknown.
- 2012-08: Study NCT00947037; Company role Lead sponsor; Phase Phase 2; Status Withdrawn.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2018-07 | NCT03576638 Study to Assess Pharmacokinetics of Accordion Pill Carbidopa-Levodopa Compared to Immediate Release Carbidopa-Levodopa in Parkinson's Disease Patients | Lead sponsor | Phase 2 | Unknown | Parkinson Disease | 12 | 2019-01 |
| 2016-07 | NCT02615873 A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004 | Lead sponsor | Phase 3 | Unknown | Parkinson's Disease | 460 | 2019-12 |
| 2016-03 | NCT02605434 A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients | Lead sponsor | Phase 3 | Unknown | Parkinson's Disease | 420 | 2019-12 |
| 2012-08 | NCT00947037 Gastric Retentive Carbidopa/ Levodopa in Parkinson's Patients; a One Year, Open Label, Safety Extension Study | Lead sponsor | Phase 2 | Withdrawn | Parkinson's Disease | 0 | |
| 2011-01 | NCT01277107 A Polysomnographic Study to Compare the Efficacy of Gastric Retentive Zaleplon Accordion Pill to Placebo in Subjects With Insomnia | Lead sponsor | Phase 2 | Completed | Insomnia | 83 | 2011-09 |
| 2010-09 | NCT01196650 Comparison of IN 10 003 to Placebo in Subjects With Insomnia Suffering From Difficulty in Falling Asleep and Staying Asleep | Lead sponsor | Phase 2 | Completed | Subjects With Insomnia Suffering From Difficulty in Falling Asleep and Staying Asleep | 24 | |
| 2009-07 | NCT00918177 An Evaluation of the Pharmacokinetics and Pharmacodynamics of AP09004 in Patients With Parkinson's Disease | Lead sponsor | Phase 2 | Completed | Parkinson's Disease | 72 |